1. Home
  2. YDES vs KBDC Comparison

YDES vs KBDC Comparison

Compare YDES & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDES

YD Bio Limited Ordinary Shares

N/A

Current Price

$8.15

Market Cap

894.2M

Sector

N/A

ML Signal

N/A

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$13.68

Market Cap

941.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDES
KBDC
Founded
2013
2021
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
894.2M
941.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
YDES
KBDC
Price
$8.15
$13.68
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$15.50
AVG Volume (30 Days)
15.4K
423.2K
Earning Date
01-01-0001
06-04-2026
Dividend Yield
N/A
13.66%
EPS Growth
N/A
N/A
EPS
N/A
1.67
Revenue
N/A
N/A
Revenue This Year
N/A
$193.84
Revenue Next Year
N/A
$9.00
P/E Ratio
N/A
$8.32
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$13.06
52 Week High
$25.00
$16.98

Technical Indicators

Market Signals
Indicator
YDES
KBDC
Relative Strength Index (RSI) 33.77 42.61
Support Level $8.12 $13.54
Resistance Level $9.46 $15.25
Average True Range (ATR) 0.64 0.36
MACD 0.03 0.03
Stochastic Oscillator 7.32 52.09

Price Performance

Historical Comparison
YDES
KBDC

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

Share on Social Networks: